Search company, investor...

Spinifex

spinifexpharma.com

Founded Year

2005

Stage

Acquired | Acquired

Total Raised

$75.18M

Valuation

$0000 

About Spinifex

Spinifex Pharmaceuticals is a US-Australian biotechnology company developing new drug candidates for the treatment and management of pain. Established in 2005 and based in Stamford, Connecticut and Melbourne, Australia, Spinifex has applied its world-class drug development capabilities to advance product candidates. Its lead product EMA401 is under development as a potential first-in-class oral treatment for chronic pain without CNS side effects. Spinifex's Phase 2 program for EMA401 includes clinical trials in a number of chronic pain conditions.

Headquarters Location

Corporate One Suite G5, 84 Hotham St

Preston, Victoria, 3072,

Australia

+61 (0)3 9863 6820

Missing: Spinifex's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Spinifex's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Spinifex

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Spinifex is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Spinifex Patents

Spinifex has filed 14 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

1/4/2013

4/18/2017

Rare diseases, Pyrrolidines, Analgesics, G protein coupled receptors, Trifluoromethyl compounds

Grant

Application Date

1/4/2013

Grant Date

4/18/2017

Title

Related Topics

Rare diseases, Pyrrolidines, Analgesics, G protein coupled receptors, Trifluoromethyl compounds

Status

Grant

Latest Spinifex News

Wind farm could power Portland aluminum smelter

Oct 6, 2022

The Australian Renewable Energy Agency (ARENA) has announced $1.5 million in funding to Spinifex Offshore Wind Farm to back its study the potential for a 1,000 MW offshore wind farm project off the coast of Portland, Victoria to power the local smelter. Spinifex, a subsidiary of Alinta Energy, will conduct a wind resource assessment and… The post Wind farm could power Portland aluminum smelter appeared first on Australian Manufacturing Forum.

Spinifex Frequently Asked Questions (FAQ)

  • When was Spinifex founded?

    Spinifex was founded in 2005.

  • Where is Spinifex's headquarters?

    Spinifex's headquarters is located at Corporate One, Preston.

  • What is Spinifex's latest funding round?

    Spinifex's latest funding round is Acquired.

  • How much did Spinifex raise?

    Spinifex raised a total of $75.18M.

  • Who are the investors of Spinifex?

    Investors of Spinifex include Novartis, UniSeed, Brandon Capital, GBS Venture Partners, Canaan Partners and 4 more.

  • Who are Spinifex's competitors?

    Competitors of Spinifex include Asuragen, Viridian Therapeutics, Cerenis Therapeutics, Tolera Therapeutics, Cara Therapeutics and 11 more.

Compare Spinifex to Competitors

D
Delphic Diagnostics

Delphic aims to provide a full suite of HIV diagnostics, from simple viral load testing through to advanced genetic tests, to pharmaceutical organisations and clinicians. Some of Delphic's tests are and have been developed internally. As part of MMC's investment, the University of Liverpool's Therapeutic Drug Monitoring service, was "˜spun in' to the business.

I
Intarcia Therapeutics

Intarcia Therapeutics is a biopharmaceutical company based in Boston, Massachusetts. Intarcia is engaged in the development of a pipeline of products for the proprietary Medici Drug Delivery System comprised of three technologies: A stabilization technology that allows for proteins, peptides, antibody fragments, and other highly potent small molecules to be stabilized at or above human body temperatures, a matchstick-sized osmotic mini-pump that is placed under the dermal layer of skin to deliver a continuous and consistent flow of medication, and a placement technology including proprietary tools designed to provide an optimal user experience.

K
Keystone Nano

Keystone Nano seeks to improve human health by creating new ways to diagnose and treat human diseases and improve the quality of life. Keystone Nano partners with healthcare companies to the development and speed the market launch of nano-enabled therapeutics to seek/treat/image a variety of conditions.

CoImmune Logo
CoImmune

CoImmune, fka Argos Therapeutics, is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases. Using biological components from each patient, the company's immunotherapies employ the patient's dendritic cells to activate an immune response specific to the patient's disease.

J
JadoLabs

JADO aims to become the leader in the emerging field of Raft intervention therapeutics, through the development of pharmaceutical products with potential for treating a range of human diseases. RAFTs are sub-compartments of cell membranes that play an integral role in key biological pathways. Using its drug development platform, called Raft Intervention Technology, JADO is exploiting new insights and understanding of cell membrane chemistry and organization that aims to enable us to address difficult to treat diseases, such as allergies (atopic dermatitis, asthma), viral and bacterial infections, cancer, neurodegenerative diseases (Alzheimer's) and metabolic illnesses (diabetes, lipid storage diseases).

N
Neurotide

Neurotide is developing pain killers based on the body's own natural pain killer, endomorphin. Synthesised endomorphin can relieve pain when delivered directly to the brain, but has a short life span and is unsuitable as a drug without modifications. Neurotide is developing an orally available form of endomorphin for the treatment of chronic and acute pain as well as a new treatment for neuropathic pain, which can be caused by diabetes, injury and certain infections.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.